Abstract
CAB represents the gold standard of treatment for patients with advanced prostate cancer. The treatment is well-tolerated with the only increased side effect being a 6% increase in diarrhea. Ninety-five percent of patients benefit, and those having minimal metastatic disease show a marked benefit. Since maximal androgen blockade seems to be of major benefit for patients with good performance status and minimal disease, its role needs to be investigated in patients with earlier stages of prostate cancer including stages B, C, and D1. Important trials are underway to address these provocative issues. Progress in the treatment of patients who relapse with metastatic prostate cancer after initial CAB will probably come to rely on the discovery and development of novel drugs or innovative drug delivery systems. Immunomodulatory drugs to enhance the body's natural defenses, monoclonal antibodies directed against prostate specific cellular antigens and tagged with radioisotopes or cytotoxic agents, and bone-seeking radiopharmaceuticals may represent the breakthrough that is needed. Exciting advances in gene therapy may represent the ultimate chance for a cure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of clinical endocrinology and metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
